Mariathasan et al. observed that the therapeutic combination of TGF-β blockade and anti-PD-L1 pathways can decrease TGF-β signaling in the TME and reshape the TME by enhancing anti-tumor activity by disrupting T cell infiltration. This evidence concerns the gene CD274 and neoplasm.